Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 3, 2016, Pages 728-733

  Katzelnick, Leah C ^a,b   Montoya, Magelda ^b   Gresh, Lionel ^c   Balmaseda, Angel ^d   Harris, Eva ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Sustainable Sciences Institute   (Nicaragua)

^d Ministry of Health   (Nicaragua)

Author keywords

Cohort study; Dengue virus; Neutralizing antibodies; Nicaragua; Protection

Indexed keywords

CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; ENDEMIC DISEASE; HUMAN; LONGITUDINAL STUDY; NICARAGUA; NONHUMAN; PRIORITY JOURNAL; SECONDARY INFECTION; SYMPTOMATOLOGY; VIRUS STRAIN; IMMUNOLOGY; PRESCHOOL CHILD; SEROTYPING; VIROLOGY;

ADOLESCENT; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; HUMANS; LONGITUDINAL STUDIES; NICARAGUA; SEROTYPING;

EID: 84955094853     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522136113     Document Type: Article

References (37)

1. Bhatt S, et al. (2013) The global distribution and burden of dengue. Nature 496(7446): 504-507.
2. Guzman MG, Harris E (2015) Dengue. Lancet 385(9966):453-465.
3. Holmes EC, Twiddy SS (2003) The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 3(1):19-28.
4. Hammon WM, Rudnick A, Sather GE (1960) Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 131(3407):1102-1103.
5. Guzman MG, et al. (2007) Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13(2):282-286.
6. Sabin AB (1952) Research on dengue during World War II. Am J Trop Med Hyg 1(1):30-50.
7. Anderson KB, et al. (2014) A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 209(3):360-368.
8. Reich NG, et al. (2013) Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface 10(86):20130414.
9. Montoya M, et al. (2013) Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 7(8):e2357.
10. Sangkawibha N, et al. (1984) Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120(5): 653-669.
11. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140(4):527-533.
12. Olkowski S, et al. (2013) Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208(6):1026-1033.
13. Sabchareon A, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 380(9853):1559-1567.
14. Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38(2):411-419.
15. Simmons CP, et al. (2007) Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196(3):416-424.
16. Libraty DH, et al. (2009) A prospective nested case-control study of Dengue in infants: Rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6(10):e1000171.
17. Endy TP, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189(6):990-1000.
18. Buddhari D, et al. (2014) Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis 8(10):e3230.
19. Corbett KS, et al. (2015) Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis 211(4):590-599.
20. Balmaseda A, et al. (2010) Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 201(1):5-14.
21. Gordon A, et al. (2013) The Nicaraguan pediatric dengue cohort study: Incidence of inapparent and symptomatic dengue virus infections, 2004-2010. PLoS Negl Trop Dis 7(9):e2462.
22. Mattia K, et al. (2011) Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 6(11):e27252.
23. Nisalak A, et al. (2003) Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68(2):191-202.
24. Morrison AC, et al. (2010) Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: Interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis 4(5):e670.
25. Gutierrez G, et al. (2011) Unusual dengue virus 3 epidemic in Nicaragua, 2009. PLoS Negl Trop Dis 5(11):e1394.
26. Grange L, et al. (2014) Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol 5(JUN):280.
27. Balmaseda A, et al. (2006) Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg 74(3):449-456.
28. OhAinle M, Harris E (2014) Dengue pathogenesis: Viral factors. Dengue and Dengue Hemorrhagic Fever, eds Gubler DJ, Ooi EE, Vasudevan SG, Farrar J (CAB International, Wallingford, U.K.), 2nd Ed, pp 231-250.
29. OhAinle M, et al. (2011) Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 3(114):114ra128.
30. Kochel TJ, et al. (2002) Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 360(9329):310-312.
31. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM (2003) Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 9(7):800-809.
32. Katzelnick LC, et al. (2015) Dengue viruses cluster antigenically but not as discrete serotypes. Science 349(6254):1338-1343.
33. Puschnik A, et al. (2013) Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 7(6):e2274.
34. Halstead SB, Casals J, Shotwell H, Palumbo N (1973) Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections. Am J Trop Med Hyg 22(3):365-374.
35. Bernardo L, et al. (2008) Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15(3):439-446.
36. Nagao Y, Koelle K (2008) Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc Natl Acad Sci USA 105(6):2238-2243.
37. Mood C (2010) Logistic regression: Why we cannot do what we think we can do, and what we can do about it. Eur Sociol Rev 26(1):67-82.